TITLE

Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies

AUTHOR(S)
Lai, Jeffrey K. C.; Lucas, Robyn M.; Clements, Mark S.; Roddam, Andrew W.; Banks, Emily
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10 Issue 1, p331
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Vitamin D supplementation for fracture prevention is widespread despite conflicting interpretation of relevant randomised controlled trial (RCT) evidence. This study summarises quantitatively the current evidence from RCTs and observational studies regarding vitamin D, parathyroid hormone (PTH) and hip fracture risk. Methods: We undertook separate meta-analyses of RCTs examining vitamin D supplementation and hip fracture, and observational studies of serum vitamin D status (25-hydroxyvitamin D (25(OH)D) level), PTH and hip fracture. Results from RCTs were combined using the reported hazard ratios/relative risks (RR). Results from case-control studies were combined using the ratio of 25(OH)D and PTH measurements of hip fracture cases compared with controls. Original published studies of vitamin D, PTH and hip fracture were identified through PubMed and Web of Science databases, searches of reference lists and forward citations of key papers. Results: The seven eligible RCTs identified showed no significant difference in hip fracture risk in those randomised to cholecalciferol or ergocalciferol supplementation versus placebo/control (RR = 1.13[95%CI 0.98-1.29]; 801 cases), with no significant difference between trials of <800 IU/day and ⩾800 IU/day. The 17 identified case-control studies found 33% lower serum 25(OH)D levels in cases compared to controls, based on 1903 cases. This difference was significantly greater in studies with population-based compared to hospital-based controls (?2 1 (heterogeneity) = 51.02, p < 0.001) and significant heterogeneity was present overall (?2 16 (heterogeneity) = 137.9, p < 0.001). Serum PTH levels in hip fracture cases did not differ significantly from controls, based on ten case-control studies with 905 cases (?2 9 (heterogeneity) = 149.68, p < 0.001). Conclusions: Neither higher nor lower dose vitamin D supplementation prevented hip fracture. Randomised and observational data on vitamin D and hip fracture appear to differ. The reason for this is unclear; one possible explanation is uncontrolled confounding in observational studies. Post-fracture PTH levels are unrelated to hip fracture risk.
ACCESSION #
52839529

 

Related Articles

  • Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Lundkvist, J.; Johnell, O.; Cooper, C.; Sykes, D. // Osteoporosis International;Feb2006, Vol. 17 Issue 2, p201 

    Parathyroid hormone (PTH) is a new treatment for osteoporosis and has been shown to reduce the risks of vertebral and non-vertebral fractures in postmenopausal women in clinical trials. The objective of this study was to estimate the cost-effectiveness of teriparatide in addition to calcium and...

  • Do calcium and vit D supplements help prevent fractures? Sahota, Opinder // Pulse;9/23/2005, Vol. 65 Issue 37, p60 

    Examines whether calcium and vitamin D supplements help prevent fractures. Value of prescribing calcium and vitamin D in elderly patients; Confusion over the issue of whether calcium and vitamin D reduce fractures in the elderly living in care homes; Role of calcium and vitamin D on...

  • Cellular Responses to 24R,25-dihydroxyvitamin D3 in Bone and Cartilage. Boyan, B. D.; Hurst-Kennedy, J.; Denison, T. A.; Schwartz, Z. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Sep2009, Vol. 9 Issue 3, p137 

    In this review, we will summarize recent findings surrounding the physiological actions of 24R,25-dihydroxyvitamin D3 [24,25(OH)2D3], an active vitamin D3 metabolite that regulates endochondral ossification and bone fracture healing. 24,25(OH)2D3 exerts rapid effects in resting zone growth plate...

  • Doubt over ability of calcium and vitamin D to prevent fractures.  // Practice Nurse;5/13/2005, Vol. 29 Issue 9, p6 

    Presents the findings of studies on doubts over the benefits provided by calcium and vitamin D to prevent fractures. Ineffectiveness of supplements; Treatment options for people with osteoporosis.

  • Vitamin D Analogs Versus Native Vitamin D in Preventing Bone Loss and Osteoporosis-Related Fractures: A Comparative Meta-analysis. Richy, F.; Schacht, E.; Bruyere, O.; Ethgen, O.; Gourlay, M.; Reginster, J.-Y. // Calcified Tissue International;Mar2005, Vol. 76 Issue 3, p176 

    It has been suggested that early postmenopausal women and patients treated with steroids should receive preventive therapy (calcium, vitamin D, vitamin D analogs, estrogens, or bisphosphonates) to preserve their bone mineral density (BMD) and to avoid fragility fractures. We designed the present...

  • Mechanism and Potential of the Growth-Inhibitory Actions of Vitamin D and Analogs. Eelen, G.; Gysemans, C.; Verlinden, L.; Vanoirbeek, E.; De Clercq, P.; Van Haver, D.; Mathieu, C.; Bouillon, R.; Verstuyf, A. // Current Medicinal Chemistry;2007, Vol. 14 Issue 17, p1893 

    1a,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] can exert its biological actions through binding with the nuclear vitamin D receptor (VDR), a ligand-activated transcription factor. Next to control of bone and mineral homeostasis, these actions include an immunomodulatory effect and a potent...

  • If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary. Hutchinson, Michael // Multiple Sclerosis Journal;Feb2013, Vol. 19 Issue 2, p143 

    The author discusses the indirect sources of evidence to support the hypothesis that large doses of Vitamin C is a strong immune modulator and that Vitamin D deficiency is a major factor both in severity and susceptibility of multiple sclerosis (MS). He states the importance of the national MS...

  • Resolving Vitamin D Deficiency in the Preconception Period among High-Risk Reproductive Women: A Randomized Controlled Trial. Taheri, Mahshid; Baheiraei, Azam; Foroushani, Abbas Rahimi; Modarres, Maryam // Iranian Red Crescent Medical Journal;Jan2014, Vol. 16 Issue 1, p1 

    Background: Although vitamin D deficiency has been linked to potential complications in reproductive women, the recommended intake dosage of this vitamin in populations with high incidence of deficiency in preconception period has not been defined. Objectives: The study investigated the effect...

  • Review: prophylactic use of vitamin D reduces falls in older persons. Bischoff-Ferrari, H. A.; Dawson-Hughes, B.; Willett, W. C. // Evidence Based Medicine;Nov/Dec2004, Vol. 9 Issue 6, p169 

    The article reports that prophylactic use of vitamin D reduces falls in older persons. Falls are a serious concern in older persons because of their high prevalence and potential to lead to severe morbidity or mortality. The meta-analysis of 5 randomized controlled trials by researcher H.A....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics